Abintus Bio is reprogramming cells in vivo to pioneer off-the-shelf medicines. In vivo medicines involve approaches to treat disease by targeting cells within the body instead of first removing them. Abintus is using their Modular Viral Platform (MVP) to discover mechanisms to reprogram any cell type in the body to target a range of diseases. This involves identifying biologics to achieve reprogramming and methods to attain tissue specificity. Currently, Abintus has developed in vivo CAR-X products that can be used to reprogram both innate and adaptive immune effector cells to trigger a robust immune response against hematologic and solid tumors.
Claim company profile to post jobs directly on this page and this website.